2020 gets underway with the much anticipated news of the first gepant to receive marketing approval in the USA. Ubrelvy (ubrogepant) is now licensed for the acute treatment of migraine with or without aura in adults and is expected to become available in the USA in the first quarter of the year.

In new videos on the Forum, Peter Goadsby discusses remaining questions about CGRP therapy and the potential impact of targeting the CGRP pathway for both prevention and treatment of migraine:

• What next for anti-CGRP therapy?
• CGRP therapies in acute migraine

In our recent Hot Topic, Professor Byung-Kun Kim reviews the current place of CGRP therapy in Korea.

With so many key clinical trials of CGRP therapies underway or recently completed, take a look at our updated summaries at: https://www.cgrpforum.org/articles/trials/

From the last major congress of 2019 – the World Congress of Neurology – we reported progress in CGRP research and a new workplace initiative from the International Headache Society Global Patient Advocacy Coalition (IHS-GPAC).

For news of the latest important CGRP publications of the last few months, click on CGRP in the Journals.

And don’t forget to check out further regulatory approvals for CGRP therapies worldwide on our expert guide to regulatory status and indications.

Catch up on more here:

• Fresh insights on site of action for CGRP therapy
• Three-year erenumab data support safety and tolerability
• Eptinezumab is focus of planned Lundbeck takeover of Alder BioPharmaceuticals
• The World Congress of Neurology